###
中国临床研究:2022,35(2):264-266,271
本文二维码信息
码上扫一扫!
应用myPKFiT解析药代动力学指导血友病A患者个体化用药的进展
(中国医学科学院血液病医院 中国医学科学院血液学研究所 国家血液系统疾病临床医学中心 实验血液学国家重点实验室,天津 300020)
Application of myPKFiT in analyzing the pharmacokinetics to guide the progress of personalized medicine for patients with hemophilia A
(Hematology Hospital of Chinese Academy of Medical Sciences, Institute of Hematology, Chinese Academy of Medical Sciences, National Center for Hematological Diseases Clinical Medicine, State Key Laboratory of Experimental Hematology, Tianjin 300020, China)
摘要
本文已被:浏览 817次   下载 344
投稿时间:2021-07-12   网络发布日期:2022-02-20
中文摘要: myPKFiT是药代动力学(pharmacokinetic,PK)指导下的A型血友病管理工具,能够快速准确地输出患者PK参数和给药方案供临床参考。目前血友病A的标准治疗手段为预防治疗,然而由于个体间差异的影响,仅以体重为参考来计算凝血因子Ⅷ(FⅧ)的用量,并不能满足血友病A患者的个体化治疗需求。PK参数可以协助临床医生更好地制订个体化治疗方案,从而改善血友病患者的治疗效果和生活质量。本文将对应用myPKFiT解析PK指导血友病A患者个体化用药的进展进行概述。
Abstract:myPKFiT is a hemophilia A management tool under the guidance of pharmacokinetic (PK), which can quickly and accurately output patient PK parameters and dosing schedules for clinical reference. The current standard treatment for hemophilia A is preventive treatment. However, due to the influence of differences between individuals, calculating the dosage of coagulation factor Ⅷ (FⅧ) based on body weight alone cannot meet the individualized treatment needs of patients with hemophilia A. PK parameters can help clinicians better formulate individualized treatment plans, thereby improving the treatment effect and quality of life of patients with hemophilia. This article will give an overview of the progress of using myPKFiT to analyze PK to guide personalized medicine for patients with hemophilia A.
文章编号:     中图分类号:R973 R554+.1    文献标志码:B
基金项目:
附件
引用文本:
张文慧,杨仁池.应用myPKFiT解析药代动力学指导血友病A患者个体化用药的进展[J].中国临床研究,2022,35(2):264-266,271.

用微信扫一扫

用微信扫一扫